The Global Partnership on Drug Policies and Development (GPDPD) operates under the political patronage of the German Federal Government’s Drug Commissioner, Marlene Mortler, who has also assumed chairmanship of the political steering committee.
As patron, the Drug Commissioner coordinates the programme with its principal, the Federal Ministry for Economic Cooperation and Development (BMZ). A procedural agreement has been reached to regulate cooperation between the two institutions, representing a first in the German Federal Government's drug policy.
The Drug Commissioner works on the international level to promote a balanced drug policy. This builds on the four pillars of the German Federal Government's drug policy: prevention of drug use, counselling and treatment of drug addicts, harm reduction and criminal-law measures.
This drug policy concept is human-centred, putting emphasis on people’s needs. It is reflected internationally in the efforts of the Federal Government and the Drug Commissioner towards the establishment of a third path in drug policy, based on rationality. Thus it is strongly oriented towards development and health policy guidelines, without either pursuing a laisser-faire policy or relying on repressive measures. A crucial role is played by the alternative development approach, a method entailing measures to promote alternative sources of income for small farmers involved in the cultivation of drug crops.
"But I am convinced that our drug policy needs a further building block: an effective alternative development policy. People who depend on the cultivation of drug crops to earn their livelihood need real alternatives. Need financial support, help for self-help. That is why Germany has created a new programme, the "Global Partnership on Drug Policies and Development"."
German Federal Government’s Drug Commissioner, Marlene Mortler – speech at UNGASS (20.04.2016)
Harm reduction, in the sense of minimising negative consequences associated with the use of drugs, is another approach that the German Federal Government's Drug Commissioner promotes on the international level. In this context, the focus is particularly on Africa, Asia and Latin America.